Loading...
XNAS
PRPH
Market cap360kUSD
Jul 10, Last price  
0.08USD
1D
0.13%
1Q
-28.21%
Jan 2017
-99.62%
Name

Prophase Labs Inc

Chart & Performance

D1W1MN
XNAS:PRPH chart
P/E
P/S
0.08
EPS
Div Yield, %
Shrs. gr., 5y
48.91%
Rev. gr., 5y
-21.43%
Revenues
4m
-35.82%
42,124,96939,475,38120,506,61219,816,00014,502,00017,453,00022,406,00025,032,00022,070,00020,604,00021,014,0009,867,00013,126,0009,876,00014,514,00079,042,000122,647,00044,384,0006,770,0004,345,000
Net income
-15m
L-72.37%
-1,748,345-2,458,337-5,534,286-3,842,000-3,501,000-2,710,000-1,091,000405,000-7,834,000-3,600,000-2,868,00041,831,000-1,740,000-3,146,000-2,125,0006,273,00018,463,000-16,782,000-53,364,000-14,743,000
CFO
-8m
L-52.42%
956,943-1,311,598-3,057,592445,000-3,549,000-2,108,000-5,729,0001,137,000-3,216,000-3,497,000-472,000-2,838,000-2,119,000-841,000-2,592,000-13,619,00028,551,000-11,348,000-17,538,000-8,344,000
Dividend
May 24, 20223 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

ProPhase Labs, Inc., founded in 1989 in Garden City, New York (and previously known as The Quigley Corporation), operates as a diversified company with two main areas of focus: Consumer Products and Diagnostic Services. Through its Consumer Products division, ProPhase Labs is actively involved in the entire process—from researching and developing to manufacturing, distributing, marketing, and selling—a range of over-the-counter (OTC) healthcare items and nutritional supplements within the United States. Notable offerings include dietary supplements like Legendz XL, which supports male sexual health, and Triple Edge XL, formulated to enhance energy and stamina. The Diagnostic Services segment provides crucial testing solutions, including PCR tests for SARS-CoV-2 (COVID-19) and its variant mutations, using both saliva and nasal swab collection methods. This segment also offers molecular testing for other respiratory pathogens and supplies personal genomics products and services. Additionally, ProPhase Labs extends its capabilities by providing comprehensive contract manufacturing services, covering product development, pre-commercialization activities, production, warehousing, and distribution. The company's diverse products and services reach consumers through a broad network of national chain drug stores, various regional retailers, and online platforms.
IPO date
Jan 16, 1984
Employees
129
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT